Atypical antipsychotics for the treatment of bipolar disorder: More shadows than lights

CNS Drugs

Volumn 21, Issue 5, 2007, Pages 367-387

  Gentile, Salvatore ^a  

^a ASL Salerno 1   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADD ON THERAPY; AGITATION; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DEPRESSION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ECG ABNORMALITY; EDEMA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEADACHE; HUMAN; HYPERKINESIA; HYPOMANIA; INCREASED APPETITE; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; LIMB PAIN; LIPID METABOLISM; LONG TERM CARE; MAINTENANCE THERAPY; MANIA; METABOLIC DISORDER; MIXED MANIA AND DEPRESSION; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROPHYLAXIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; RHINITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; VAGINITIS; WEIGHT CHANGE; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS; HUMANS;

EID: 34248198037     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721050-00002     Document Type: Review

References (123)

1. World Health Organization. World health report. Mental health: new understanding, new hope. Geneva: World Health Organization, 2001
2. Swann A. Practical management of depressive and manic episodes. In: Garza-Trevino ES, ed. Medical psychiatry: theory and practice. Vol. 1. Teaneck (NJ). World Scientific, 1989
3. Harma BJ, Nasrallah HA, Clancy J, et al. Psychiatric diagnosis and risk for tardive dyskinesia. Arch Gen Psychiatry 1993; 40: 346-7
4. Cavazzoni P, Berg PH, Kryhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006; 67: 107-13
5. Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. Br J Psychiatry 1995; 166: 375-81
6. Keck Jr PE, McElroy SL. Redefining mood stabilization. J Affect Dis 2003; 73: 163-9
7. CenterWatch, Clinical Trials Listing Service™. Drugs approved by the FDA [online]. Available from URL: http://www.centerwatch.com/patient/drugs/ dru545.html [Accessed 2006 May 1]
8. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88
9. Swann AC, Secunda SK, Katz MM, et al. Lithium treatment of mania: clinical characteristics, specificity of symptom change, and outcome. Psychiatr Res 1986; 118: 127-41
10. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 1981; 64: 226-37
11. Esparon J, Kolloori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986; 148: 723-5
12. Judd L, Akiskal H, Schletter P, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-7
13. Zarate Jr CA. Antipsychotic drug side effect issues in bipolar manic patients. J Clin Psychiatry 2000; 61 Suppl. 8: 52-61
14. Miller DS, Latham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J Clin Psychiatry 2001; 62 (12): 975-80
15. Gentile S. Long-term atypical antipsychotic treatment and risk of weight gain: a literature analysis. Drug Saf 2006; 29 (4): 303-19
16. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004; 71: 195-212
17. Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring, and management. Bipol Disord 2003; 5 Suppl. 2: 62-79
18. Gentile S. Antipsychotic-associated weight gain [letter]. Ann Pharmacother 2004; 38: 903
19. Guille C, Sachs G, Ghaemi S. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000; 61: 638-42
20. Liebermann JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005; 353 (12): 1209-23
21. Zyprexa (olanzapine) tablets and Zyprexa Zydis (olanzapine) orally disintegrating tablets (prescribing information). Indianapolis (IN): Eli Lilly and Company, 2004
22. Abilify (aripiprazole) tablets and oral solution (prescribing information). Princeton (NJ): Bristol-Myers Squibb Company, 2005; Rockville (MD): Otsuka America Pharmaceutical, Inc., 2005
23. Department of Health and Human Services, Public Health Service, Food and Drug Administration. Supplemental new drug (Seroquel®) application. Rockville (MD): Department of Health and Human Services, 2006 Oct 20
24. Padala PR, Wengel SP, Petty F. Manic episode during treatment with aripiprazole [letter]. Am J Psychiatry 2007; 164 (1): 172-3
25. Keck Jr PE, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651-8
26. Keck Jr PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626-37
27. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole in acute bipolar mania. Br J Psychiatry 2005; 187: 235-42
28. Lykouras L, Gournellis R, Angelopoulos E. Manic symptoms induced by olanzapine. Eur Neuropsychopharmacol 2001; 11 (2): 97-8
29. Benazzi F. Olanzapine-induced psychotic mania in bipolar schizo-affective disorder. Eur Psychiatry 1999; 14 (7): 410-1
30. Simon AE, Aubry JM, Malky L, et al. Hypomania-like syndrome induced by olanzapine. Int Clin Psychopharmacol 1999; 14 (6): 377-8
31. Fitz-Gerald MJ, Pinkofsky HB, Brannon G, et al. Olanzapine-induced mania [letter]. Am J Psychiatry 1999; 156: 1114
32. Pozo P, Alcantara AG. Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment. J Psychiatry Neurosci 1988; 23 (5): 309-10
33. Reeves RR, McBride WA, Brannon GE. Olanzapine-induced mania. J Am Osteopath Assoc 1998; 98 (10): 549-50
34. Lyndenmayer JP, Klebanov R. Olanzapine-induced manic-like syndrome. J Clin Psychiatry 1998; 59 (6): 318-9
35. London JA. Mania associated with olanzapine. J Am Acad Child Adolesc Psychiatry 1998; 37 (2): 135-6
36. Henry C, Demoted-Mainard J. Olanzapine-induced mania in bipolar disorder [letter]. Rev Psychiatr Neurosci 2002; 27 (3): 200
37. Fahy S, Fahy T. Induction of manic symptoms by novel antipsychotics [letter]. Br J Psychiatry 2000; 176: 597
38. Narayan G, Puranik A. Olanzapine-induced mania. Int J Psychiatry Clin Pract 2000; 4: 333-4
39. Tohen M, Ranger TM, McElroy SL, et al. Olanzapine versus placebo in treatment of acute mania. Am J Psychiatry 1999; 156: 702-9
40. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania. Arch Gen Psychiatry 2000; 57: 841-9
41. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247-56
42. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-88
43. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar I and type II major depression: lack of manic induction. J Affect Dis 2005; 87: 121-30
44. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int J Clin Psychopharmacol 1999; 14: 339-43
45. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159: 1011-7
46. Tohen M, Chengappa KNR, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to lithium monotherapy. Arch Gen Psychiatry 2002; 59: 62-9
47. Tohen M, Chengappa KNR, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilisers v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337-45
48. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63: 1148-55
49. Brown EB, McElroy SL, Keck Jr PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. Clin Psychiatry 2006; 67: 1025-33
50. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1263-71
51. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281-9
52. Tohen M, Goldberg JF, Gonzales-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003; 60: 1218-26
53. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-60
54. Thase ME, MacFadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study). J Clin Psychopharmacol 2006; 26 (6): 600-9
55. Delbello MP, Schwiers ML, Rosemberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41 (10): 1216-23
56. Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004; 24 (6): 599-606
57. Sachs G, Chengappa KNR, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipol Disord 2004; 6: 213-33
58. McIntyre RM, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12 week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15 (5): 573-85
59. Bowden CL, Grunze H, Mullen J, et al. A randomised, double-blind, placebo-controlled efficacy of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66 (1): 111-21
60. Delbello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45 (3): 1-9
61. Atmaca M, Kuloglu M, Buyukbayram A, et al. Quetiapine-associated and dose-related hypomania in a woman with schizophrenia. Eur Psychiatry 2002; 17 (5): 292-3
62. Benazzi F. Quetiapine-associated hypomania in a woman with schizoaffective disorder. Can J Psychiatry 2001; 46 (2): 182-3
63. Pacchiarotti I, Manfredi G, Kotzalidis GD, et al. Quetiapine-induced mania [letter]. Aust N Z J Psychiatry 2003; 37 (5): 626
64. Lykouras L, Oulis P, Hatzimanolis J. Manic symptoms associated with quetiapine treatment. Eur Neuropsychopharmacol 2003; 13: 135-6
65. Biancosino B, Marmai L, Facchi A, et al. Quetiapine may induce mania: a case report. Can J Psychiatry 2003; 48: 349-50
66. Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania. Br J Psychiatry 2005; 187: 229-34
67. Hirschfeld RMA, Keck Jr PE, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161: 1057-65
68. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropsychopharmacol 1988; 21 (3): 176-80
69. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159: 1146-54
70. Yatham LN, Grossman F, Augustyns I, et al. Mood stabilizers plus risperidone or placebo in the treatment of acute mania. Br J Psychiatry 2003; 182: 141-7
71. Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005; 15: 75-84
72. Mithat B, Alpaslan T, Bulent C, et al. Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium: a case report. Pharmacopsychiatry 2005; 38: 105-6
73. Guzelcan Y, de Haan L, Scholte WF. Risperidone may induce mania. Psychopharmacology (Berl) 2002; 126 (1): 85-6
74. Zolezzi M, Badr MG. Risperidone-induced mania. Ann Pharmacother 1999; 33 (3): 380-1
75. Lane HY, Lin YC, Chang WH. Mania induced by risperidone: dose related? J Clin Psychiatry 1998; 59 (2): 85-6
76. Barkin JS, Pais Jr VM, Gaffney MF. Induction of mania by risperidone resistant to mood stabilizers. J Clin Psychopharmacol 1997; 17 (1): 57-8
77. Schnierow BJ, Graeber DA. Manic symptoms associated with initiation of risperidone. Am J Psychiatry 1996; 153 (9): 1096-7
78. Tomlison WC. Risperidone and mania. Am J Psychiatry 1996; 153 (1): 132-3
79. O'Croinin F, Zibin T, Holt L. Hypomania associated with risperidone [letter]. Can J Psychiatry 1995; 40 (1): 51
80. Gopal S, Steffens DC, Kramer ML, et al. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry 2005; 66 (8): 1016-20
81. Sundarajan V, Jainer AK. A mood stabilizer with risperidone or haloperidol for mania [letter]. Am J Psychiatry 2004; 161: 2139-40
82. Lu BY, Lundgren R, Escalona PR, et al. A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics. J Clin Psychiatry 2002; 63 (12): 1185-6
83. Davis R, Risch SC. Ziprasidone induction of hypomania in depression? Am J Psychiatry 2002; 195 (4): 673-4
84. Nolan BP, Schulte Jr JJ. Mania associated with initiation of ziprasidone [letter]. J Clin Psychiatry 2003; 64 (3): 336
85. Baldassano CF, Ballas C, Datto SM, et al. Ziprasidone-associated mania: a case series and review of the mechanism. Bipol Disord 2003; 5: 72-5
86. Larson MF, Hauser A. Possible ziprasidone-induced mania. J Am Acad Child Adolesc Psychiatry 2003; 42: 1012-3
87. Privitera MR, Maharaj K. Mania from dose-related augmentation of an SSRIs. J Clin Psychiatry 2003; 64: 1393-4
88. Brieger P. Hypomanic episodes after receiving ziprasidone: an unintended "on-off-on" course of treatment [letter]. J Clin Psychiatry 2004; 65 (1): 132
89. Keating AM, Aoun SL, Dean CE. Ziprasidone-associated mania. Clin Neuropharmacol 2005; 28 (2): 83-6
90. Keck Jr PE, Versiani M, Potkin S, et al. Ziprasidone in the treatment of bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741-8
91. Potkin SG, Keck Jr PE, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005; 25 (4): 301-10
92. Ross DE. Ziprasidone and mania [letter]. Am J Psychiatry 2004; 161 (8): 1503
93. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289 (4): 454-65
94. Boyd EA, Cho MK, Bero LA. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Acad Med 2003; 78 (8): 769-74
95. Jagadheesan K, Muirhead D. Aripiprazole for acute bipolar mania. Am J Psychiatry 2004; 161 (10): 1926-7
96. Cipriani A, Rendell J, Geddes J. Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev 2006; 3: CD004362
97. Logue DD, Gonzalez N, Heligman SD, et al. Hyperglycemia in a 7-year-old child treated with aripiprazole. Am J Psychiatry 2007; 164 (1): 173
98. ECNP Newsletter. The use of placebo in clinical trials: a continuous debate [online]. Available from URL: http://ecnp.i-site.nl/Matters/number1/ placebo.htm [Accessed 2007 Apr 2]
99. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210-6
100. Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. J Clin Psychopharmacol 2007; 27 (1): 35-45
101. Yatham LM, Kennedy SH. Canadian Network for Mood and Anxiety Treatment (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipol Disord 2005; 7 Suppl. 3: 5-69
102. Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 2006; 85 (1-3): 222-31
103. McCue R, Waheed R, Urcuyo L, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006; 189: 443-0
104. López-Muňoz A, Vieta E, Rubio G, et al. Bipolar disorder as an emerging pathology in the scientific literature: a bibliometric approach. J Affect Dis 2006; 92: 161-70
105. Rendell JM, Gijsman HJ, Keck P, et al. Olanzapine alone or in combination for acute mania. Cochrane Database Syst Rev 2003; (3): CD004040
106. Rendell JM, Gijsman HJ, Keck P, et al. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev 2006; (1): CD004043
107. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67 (4): 509-16
108. Gianfrancesco FD, Rajagopalan K, Sajatovic M, et al. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry 2006; 67 (2): 222-32
109. Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipol Disord 2006; 8: 232-41
110. Kusumakar V, Yatham L, Haslam D, et al. Treatment of mania, mixed states, and rapid cycling. Can J Psychiatry 1997; 42 Suppl. 2: S79-86
111. Bowden C, Brugger A, Swann A, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271: 918-24
112. Rachid F, Bertschy G, Bondolfi G, et al. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry 2004; 65 (11): 1537-45
113. Kahn DA, Sachs GS, Printz DJ, et al. Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines. J Psychiatr Pract 2000; 6: 197-211
114. Olanzapine: prevention of bipolar disorder: unconvincing trials. Prescrire Int 2005; 14 (78): 140-2
115. Patel NC, Crismon ML, Pondrom M. Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic. J Behav Health Serv Res 2005; 32 (4): 438-45
116. Ehret MJ, Levin GM. Long-term use of atypical antipsychotics in bipolar disorder. Pharmacother 2006; 26 (8): 1134-47
117. Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. A N Z J Psychiatry 2005; 39: 652-61
118. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149-73
119. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2004; 159: 1-50
120. Coppen A, Farmer R. Suicide mortality in patients on lithium maintenance therapy. J Affect Disord 1998; 50: 261-7
121. Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006; 8 (2): 175-81
122. Suppes T, Dennehy EB, Hirschfield RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. J Clin Psychiatry 2005; 66: 870-86
123. Gentile S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipol Disord 2006; 8 (3): 207-20